IRMD stock trades steadily as iRhythm Technologies posts strong Q2 2026 growth

IRMD stock, representing iRhythm Technologies, is trading around the mid-120 dollar range as of early September 2026, after the company reported solid Q2 2026 revenue growth and improving margins in its digital cardiac monitoring business.

IRMD stock, the market shorthand for iRhythm Technologies (ISIN US4627231087), is quoted near 123.07 dollars as of early September 2026 on its primary NASDAQ listing, placing the company firmly in the mid-cap health technology segment with a market capitalization in the low single-digit billions of USD. The current price level in early September 2026 sits well below a recent 52-week high around 179.93 dollars yet remains significantly above the 52-week low near 86.00 dollars, highlighting a wide trading range for investors who follow this digital cardiology specialist. For DACH investors, the stock can be accessed via international trading in the United States rather than a dedicated Xetra listing.

Revenue accelerates in Q2 2026

According to recent market and company data summarizing results for the second quarter of 2026, iRhythm Technologies generated Q2 2026 revenue of approximately 563.0 million USD, reflecting a clear double-digit increase versus roughly 410.0 million USD in the second quarter of 2025. This implies year-over-year growth of around 37.3 percent in Q2 2026, an expansion pace that stands out in the broader health technology sector focused on remote cardiac monitoring solutions. In parallel, adjusted earnings per share for Q2 2026 reached about 1.59 dollars compared with approximately 0.90 dollars in Q2 2025, meaning EPS expanded by nearly 0.69 dollars year-over-year, underscoring improved profitability as the company scales its subscription and service base.

Margins also moved in the right direction during Q2 2026. The adjusted gross margin for iRhythm Technologies in Q2 2026 climbed to roughly 41.4 percent, up from about 36.8 percent in Q2 2025. This 4.6 percentage-point improvement reflects both efficiency gains in device production and a richer mix of recurring digital monitoring revenue. For investors, the combination of 37.3 percent revenue growth and a 4.6 percentage-point margin expansion in Q2 2026 suggests that the company is not only increasing its top line but also converting that growth into healthier profitability.

Stock valuation and market positioning

At a share price around 123.07 dollars as of early September 2026, IRMD stock trades at a valuation that embeds expectations of continued growth in cardiac monitoring demand, but still leaves room compared with the recent 52-week high of roughly 179.93 dollars. The current level is approximately 31.6 percent below that high, while remaining around 43.1 percent above the 52-week low of about 86.00 dollars. This positioning in the trading range indicates that the market has repriced the stock from peak optimism yet continues to assign a premium for the company’s growth profile, especially in the context of rising recurring revenue and expanding margins.

Analyst sentiment toward IRMD stock reflects this balance between growth and valuation. Recent compiled views classify the shares at around 4.18 out of 5 stars, placing iRhythm Technologies in the upper tier of health technology names in multi-asset and thematic portfolios that track medtech innovation. This rating frame, combined with the Q2 2026 figures, underlines a consensus expectation that the company will maintain solid revenue growth in its digital cardiac monitoring services while gradually improving profitability.

Digital cardiac monitoring as growth engine

A key product line behind iRhythm Technologies’ growth is its wearable cardiac monitoring system, which combines a sensor patch with cloud-based analytics to detect arrhythmias and other heart rhythm abnormalities over an extended period. This offering fits squarely into the global trend toward remote and continuous monitoring of patients with cardiovascular risk, enabling physicians to receive detailed rhythm data without requiring patients to stay in hospital settings. In Q2 2026, the company’s recurring revenue from monitoring and analytics subscriptions formed a significant share of its 563.0 million USD total revenue, underscoring the importance of software and data services in its business model.

For patients and healthcare providers, the system’s value lies in the ability to capture episodic arrhythmias that standard short-duration electrocardiograms might miss. That capability, combined with secure data transmission and structured reporting, forms a strong foundation for demand growth in North America and increasingly in international markets. From an investor perspective, this shift toward subscription and data-driven revenue provides visibility and resilience, which helped support the margin improvements seen in Q2 2026 and can underpin expectations for future cash flow generation.

IRMD stock price context for investors

Looking at IRMD stock in early September 2026, the share price of around 123.07 dollars as of the latest available trading snapshot places iRhythm Technologies’ equity in a zone that is neither at the extremes of its 52-week range nor close to a new record. The current market capitalization at that price level, in the low single-digit billions of USD as of early September 2026, reflects both the company’s achieved scale in digital cardiology and the market’s judgment about its future growth potential. Given the Q2 2026 revenue growth of about 37.3 percent and the margin improvement of 4.6 percentage points, many investors will focus on whether similar dynamics can be sustained into the second half of 2026.

IRMD stock fact box

• Company: iRhythm Technologies Inc.
• ISIN: US4627231087
• Ticker: IRTC
• Trading venue: NASDAQ
• Price (as of September 5, 2026): 123.07 USD
• Market capitalization: Low single-digit billions USD (as of September 5, 2026)
• Sector / Industry: Health Technology / Medical Devices
• Index membership: Included in selected US health technology and medtech indices